Test Price
2,800 AED✅ Home Collection Available
GRHL3 Gene Van der Woude Syndrome Type 2 Genetic Test in UAE | 2,800 AED | DHA Licensed Molecular Diagnostic
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test clinical guidance for result interpretation by our DHA-licensed genetics team.
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) panel analyses the entire coding region of the GRHL3 gene to identify pathogenic variants responsible for Van der Woude syndrome type 2, a rare autosomal dominant disorder presenting with lower lip pits and cleft lip/palate. High-depth NGS enables simultaneous detection of single nucleotide variants, small insertions/deletions, and copy number changes across all exons and flanking intronic regions.
A comprehensive clinical history of the proband and a formal genetic counselling session to construct a detailed family pedigree are mandatory before sample collection. The counselling assesses inheritance patterns and informs variant interpretation according to UAE PDPL and DHA standards.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Molecular Method | High-depth NGS (Next Generation Sequencing) | Sanger sequencing of a single amplicon |
| Variant Detection | Single nucleotide, small indels, copy number changes (if covered) | Limited to point mutations and small indels |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Cost (AED) | 2,800 | ~2,500 |
| DHA Compliance | Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields | Variable |
Physician Insight & Safety Protocols
"As a consultant in medical genetics, I recognise the profound anxiety families experience when facing a potential diagnosis of Van der Woude syndrome. This NGS test provides definitive molecular confirmation that guides surgical planning and genetic counselling; however, results must always be correlated with physical findings and a detailed family pedigree. Do not rely on genetic data in isolation—multidisciplinary evaluation remains the cornerstone of safe, patient-centred care."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice
⚠️ Important Clinical Warning: Do not discontinue any prescribed medication or alter your treatment regimen without explicit instruction from your attending physician. Genetic test results are a complementary diagnostic tool and are not a substitute for ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals under 18 years must have a legal guardian’s consent and complete mandated pre-test genetic counselling in accordance with UAE regulatory standards.
- Exclusion: This test is not designed for acute medical crises; it should not replace immediate clinical assessment in emergency settings.
- Exclusion: The assay is not validated for standalone prenatal diagnosis without concurrent ultrasound and invasive sampling (amniocentesis/CVS).
- ER Red Flag: Newborns with confirmed or suspected Van der Woude syndrome who present with severe respiratory distress, cyanosis, or feeding difficulties must be taken to the nearest emergency department without delay.
- ER Red Flag: Sudden onset of aspiration pneumonia or airway obstruction requires immediate hospital attention.
Patient FAQ & Clinical Guidance
1. What is the purpose of the GRHL3 gene test for Van der Woude syndrome type 2?
This NGS test detects pathogenic mutations in the GRHL3 gene to confirm a clinical diagnosis of Van der Woude syndrome type 2. It identifies variants that cause lower lip pits, cleft lip/palate, and related craniofacial anomalies, enabling early surgical planning and genetic counselling for affected families.
2. How long do results take and what is the cost?
Turnaround time is 3–4 weeks from sample receipt and the price is 2,800 AED inclusive of all laboratory fees and DHA-compliant reporting. This interval allows rigorous NGS data analysis, bioinformatic interpretation, and a comprehensive clinical report audited by a board-certified molecular geneticist.
3. Do I need a doctor’s referral or genetic counselling?
Yes, a physician referral and pre-test genetic counselling are mandatory to interpret results accurately and comply with UAE regulations. This ensures that results are linked to the correct clinical indication and that families receive proper risk assessment and psychosocial support under UAE genetic testing standards.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Governance: This testing service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is processed, stored, and transmitted using ISO 27001-certified secure servers with end-to-end encryption.
Clinical Safety & Patient Consent: All procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that patient safety, informed consent, and clinical accountability are upheld throughout the testing pathway.
Certification & Licensing: ISO 9001:2015 – Cert No. INT/EGQ/2509DA/3139. Full DHA facility licensure for genetic diagnostic services.
Clinical & Logistical Metadata
| Test Name | GRHL3 Gene Van der Woude Syndrome Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood (2–4 mL in EDTA tube) |
| Methodology Used | High-depth Next Generation Sequencing (NGS) targeting all coding exons and flanking intronic regions of GRHL3 |
| ICD-10-CM Code | Q87.0 |
| LOINC Code | 94222-2 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians